CMC Pharmaceuticals

Name

CMC Pharmaceuticals

Legal name

CMC Pharmaceuticals, Inc.

Website

https://cmcpharm.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Solon

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. Contract Development Services: Project-based contract services for drug product development including formulation, analytical, stability studies, regulatory support, and manufacturing enablement. Revenue generated through service agreements with pharmaceutical companies, biotech firms, academic institutions, and government programs. Pricing is quote-based, tailored to project scope and stage of development.
2. Government Contracts: Multi-year government contracts for medical countermeasure development. Contract with Department of Defense valued at over $53 million over 6.5 years through Battelle partnership for nerve agent countermeasure development.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

CMC Pharmaceuticals is a small molecule Contract Development and Manufacturing Organization (CDMO) that delivers end-to-end Chemistry, Manufacturing, and Controls (CMC) drug product development services. Its offerings span pre-formulation and formulation development, analytical method development and validation, ICH stability and compatibility studies, method transfer, prototype preparation via its RAMP system, scale-up and tech transfer, CMO selection and GMP manufacturing oversight, and integrated regulatory support including IND/NDA preparation, CMC strategy, agency response, and QA/QC cGMP compliance.

Product overview

CMC Pharmaceuticals is a fully integrated drug development company (CDMO) offering end-to-end Chemistry, Manufacturing, and Controls (CMC) services. The company operates a one-partner model that integrates formulation development, analytical chemistry services, ICH stability studies, method transfer and execution, prototype preparation (RAMP), scale-up and tech transfer, CMO selection and oversight, GMP manufacturing oversight, IND/NDA preparation and review, CMC strategy and execution, agency response strategy, and QA/QC compliance services. Unlike traditional testing labs or consultants, CMC Pharma combines scientific execution with regulatory strategy in-house, providing a seamless pathway from early-stage development through commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Formulation & Process Development

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• BattellecoreStrategic or Co-development Partner · 9 September 2024CMC Pharma serves as subcontractor to Battelle on U.S. Department of Defense nerve agent countermeasure program. Contract valued at over $53 million over 6.5 years funds development of Reactivating Nerve Agent Treatment System (RNATS) through FDA approval. CMC provides laboratory development, cGMP testing, and CMO oversight.
• Medical CBRN Defense Consortium (MCDC)coreStrategic or Co-development PartnerActive participant in Medical CBRN Defense Consortium (MCDC), collaborating with government and industry partners on chemical, biological, radiological, and nuclear medical countermeasure development.
• Biopharmaceutical Manufacturing Preparedness Consortium (BioMap)minorStrategic or Co-development PartnerParticipant in BioMap consortium focused on biopharmaceutical manufacturing preparedness, supporting public-private collaboration for medical countermeasure development.
• Rapid Response Partnership Vehicle (RRPV)minorStrategic or Co-development PartnerActive member of RRPV consortium enabling rapid response capabilities for pharmaceutical development and manufacturing in support of national defense and public health preparedness.
• U.S. Department of Defense (DoD)coreStrategic or Co-development PartnerDirect and subcontract relationships with Department of Defense agencies including Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) for medical countermeasure development.
• Biomedical Advanced Research and Development Authority (BARDA)minorStrategic or Co-development PartnerCollaborates with BARDA to identify and develop new medical countermeasures for chemical, biological, radiological, and nuclear threats.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Eurofins Lancaster Laboratories: Pharmaceutical contract testing laboratory offering analytical method development, validation, and stability services under cGMP. Directly comparable to CMC Pharma's analytical/ICH stability service line.
• Hovione: Small-molecule CDMO with expertise in particle engineering, formulation development, and GMP manufacturing. Comparable to CMC Pharma on technology-agnostic formulation and complex dosage-form development.
• Ascendia Pharma: Specialty CDMO focused on small-molecule formulation development and early-stage clinical supply for injectables and ophthalmics. Closely comparable to CMC Pharma on technology-agnostic formulation, pre-clinical batches, and biotech customer base.
• Cambrex: Small-molecule API and drug product CDMO providing formulation development, analytical, and stability services. Comparable to CMC Pharma on small-molecule CMC offerings and mid-pharma/biotech client base.
• Alcami Corporation: Small-molecule CDMO offering analytical services, formulation, stability, and commercial manufacturing. Directly comparable to CMC Pharma on service breadth across early development through commercialization.
• Quotient Sciences: CDMO providing early-stage formulation development, small-scale manufacturing, and integrated clinical pharmacology services. Comparable to CMC Pharma in serving virtual/small biotech sponsors with end-to-end drug development support.
• Aenova Group: Pharmaceutical CDMO providing formulation, analytical, and manufacturing services for solid dosage forms. Comparable to CMC Pharma on traditional dosage-form focus and contract development model.

Broad incumbents

• Patheon (Thermo Fisher Scientific): Global CDMO under Thermo Fisher offering small- and large-molecule drug substance and product services. Overlaps with CMC Pharma's small-molecule formulation capabilities as part of a much broader portfolio.
• Catalent: Large-scale CDMO providing formulation, clinical and commercial manufacturing across multiple modalities. Operates broadly in the same space as CMC Pharma but focuses on later-stage and commercial-scale work, not the early-stage niche.
• Emergent BioSolutions: Biopharmaceutical company focused on medical countermeasures for CBRN threats and infectious disease, working with BARDA and DoD. Comparable to CMC Pharma on the medical countermeasure side of CMC Pharma's government work, though broader in scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cmc-pharma-inc.

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CMC Pharmaceuticals